Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and Immunogenicity of ABBV-313 in Healthy Adults
NCT07673120Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-313 (8 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events, Maximum Observed Plasma Concentration of ABBV-313 and 4 more. Started Jun 2026; status: recruiting.
02
Drugs
ABBV-313
Beyond the preview
Go deeper on NCT07673120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07673120.